IDEX Biometrics ASA IDXAF
—
0.89
0.00
0.00%
as of 24 Sep
- Market cap
- —
- P/E
- 0.0×
Follow IDXAF
Growth Flags
show if company had growth for consecutive years
| Older periods | Sep '24 | Dec '24 | Mar '25 | Jun '25 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
2.31 | 0.10 | 1.45 | 22.22 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(1.32) | (0.02) | (0.31) | (4.01) | |
P/B ratio |
0.52 | 0.02 | 5.77 | 6.50 | |
Price to Tangible BV |
0.73 | 0.02 | 0.00 | 15.02 | |
EV/Sales |
6.21 | 5.02 | 10.04 | 40.00 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(0.45) | (0.24) | (0.43) | (1.09) | |
EV/FCF |
(0.46) | (0.24) | (0.43) | (1.11) | |
Quick Ratio |
0.61 | 0.85 | 0.43 | 0.34 | |
Current Ratio |
2.16 | 2.67 | 1.65 | 1.68 | |
Net Debt/EBITDA |
(0.20) | 0.01 | (0.25) | (0.21) | |
Debt/Assets |
15.21% | 19.26% | 19.81% | 18.90% | |
Debt/Equity |
0.34 | 0.42 | 12.58 | 1.75 | |
Asset Turnover |
0.08 | 0.05 | 0.04 | 0.02 | |
Operating CF/Net income |
(1.68) | 0.90 | 0.66 | 0.72 | |
Capex/Depreciation |
0.08 | (0.06) | 0.00 | 0.00 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
2,321.67% | (687.50%) | 524.04% | 656.79% | |
Selling, General and Administrative Expense of Revenue |
3,096.67% | 5,245.83% | 854.81% | 838.27% | |
Intangible Assets out of Total Assets |
0.12 | 0.06 | 0.06 | 0.06 | |
Share Based Compensation of Revenue |
121.67% | 420.83% | (165.38%) | (206.17%) | |
Graham Net Nets |
1.10 | 44.27 | (0.93) | 0.02 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(579.77%) | (17,829.00%) | (2,064.10%) | (67.05%) | |
Free Cash Flow Yield |
(588.03%) | (21,005.16%) | (1,595.64%) | (162.62%) | |
Revenue per Share |
0.02 | 0.01 | 0.01 | 0.00 | |
Operating CF per Share |
(0.73) | (0.81) | (0.33) | (0.05) | |
Capex per Share |
(0.01) | (0.02) | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.74) | (0.83) | (0.33) | (0.05) | |
Cash per Share |
0.35 | 0.49 | 0.13 | 0.03 | |
Shareholders Equity per Share |
1.83 | 1.14 | 0.02 | 0.03 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.83 | 1.14 | 0.02 | 0.03 | |
Free Cash Flow |
(2.31) | (3.42) | (2.72) | (1.49) | |
Working Capital |
5.68 | 5.79 | 3.23 | 3.11 | |
Capital Expenditures |
(0.03) | (0.08) | — | — | |
Net Current Asset Value |
3.31 | 3.67 | (0.77) | 0.13 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.50 | 3.25 | 0.00 | 0.00 | |
Net Profit Margin |
2,266.67% | (15,500.00%) | (3,984.62%) | (2,555.56%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
2.27 | 1.43 | 1.71 | 1.31 | |
Average Payables |
1.45 | 0.77 | 0.84 | 1.26 | |
Average Inventory |
6.87 | 5.97 | 5.97 | 5.93 | |
Average Assets |
16.48 | 17.63 | 13.25 | 11.55 | |
Average Common Equity |
9.45 | 8.02 | 3.20 | 1.71 |
Columns are period end dates